Exploring Gastrointestinal Symptoms And Their Impact on Quality of Life in Patients with Neuroendocrine Tumours Abstract #1470

Introduction: Treatments in NETs have been studied for effects on tumour progression and carcinoid syndrome with minimal evidence on gastrointestinal(GI) symptom burden and impact on quality of life(QoL)
Aim(s): To determine whether patients with NETs receiving treatment experience GI symptoms, and to explore their impact on QoL
Materials and methods: A prospective cohort of 46 patients with histologically confirmed NET visiting endocrine and oncology clinics completed GSRS(gastrointestinal symptom rating scale) and EORTC QLQ-GINET21 QoL questionnaires prior to establishment of a gastroenterology NET service
Conference: 13th Annual ENETS conference 2016 (2016)
Category: ...none of the above
Presenting Author: Dr Mohid Khan

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1466 Delays in Diagnosing Neuroendocrine Tumours by Secondary Care Specialities
Introduction: Gastroenteropancreatic neuroendocrine tumours (GEP-NETs) are considered to be a diagnostic challenge, many patients presenting with metastatic disease to a number of specialities in secondary care
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Dr Mohid Khan
Authors: Benny A, Ng S, Reid K, Williams M, ...
#1835 A Prospective Service Evaluation of Systematic Gastroenterological Assessment and Management on Patients with Neuroendocrine Tumours in South East Wales
Introduction: Patients with NETs can experience gastrointestinal(GI) symptoms including diarrhoea, steatorrhoea and urgency.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: ...none of the above
Presenting Author: Dr Mohid Khan
#1837 Evaluation of Faecal Elastase 1 in Symptomatic Patients with Neuroendocrine Tumours
Introduction: There is limited data on exocrine pancreatic insufficiency in patients on somatostatin analogues(SSA) which affects quality of life in NETs.
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Biomarkers
Presenting Author: Dr Mohid Khan
#2708 Patient Reported Symptoms, Coping and Quality of Life during Somatostatin Analogue Treatment for Metastatic Small-Intestinal Neuroendocrine Tumours
Introduction: Patients with metastatic small-intestinal neuroendocrine tumours (NET) have been shown to have a reduced quality of life compared to the general population and many have disabling symptoms during somatostatin analogue (SSA) treatment.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Prof Halfdan Sorbye
#43 Relationship between neuroendocrine tumor-related symptoms and RAND-36 health-related quality of life scores
Introduction: Neuroendocrine tumors (NETs) can secrete hormones that cause flushing and diarrhea (carcinoid syndrome) and disrupt health-related quality of life (HRQL).
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Jennifer L Beaumont
Authors: Beaumont J L, Liu Z, Choi S, Yao J C, ...